Daiichi to market Nycomed imaging agent in Japan:
This article was originally published in Clinica
Daiichi is to market Nycomed Amersham's ultrasound imaging agent, NC-100100, in Japan. The product will be used in cardiology and radiology applications, including liver imaging. It will be submitted for approval in the US and Europe at the end of this year. Development in Japan is at the preclinical stage. Daiichi already markets selected Nycomed imaging agents in Japan, including the non-ionic X-ray contrast medium, Omnipaque (iohexol). Nycomed Amersham estimates the potential worldwide market for ultrasound imaging to be around $1.6 billion.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.